Surgery Websites
Thoracic Oncology Program »  Meet the Team »  Medical Oncologists »  Collin Blakely, M.D., Ph.D.
Collin Blakely, M.D., Ph.D.

Collin Blakely, M.D., Ph.D.

Assistant Clinical Professor
Division of Hematology/Oncology
Department of Medicine

Contact Information

(415) 885-3882  Patients & Clinic 
(415) 353-9525  Fax
Open Popup

University of Washington, B.S. 1997
University of Pennsylvania, M.D., Ph.D. 2007

  • Hospital of the University of Pennsylvania, Internship in Internal Medicine, 2007-2008

  • Hospital of the University of Pennsylvania, Residency in Internal Medicine, 2008-2009
  • UCSF, Fellowship in Medical Oncology, 2009-2011
  • Postdoctoral Fellow - UCSF, Lisa Coussens Laboratory, 2010-2012

  • Postdoctoral Fellow - UCSF, Trever Bivona Laboratory, 2012-2014
  • Non-small cell lung cancer
  • Small cell lung cancer
  • ALK-rearranged lung cancer
  • EGFR-mutant lung cancer
  • Mechanisms of resistance to targeted therapies
  • ROS1-rearranged lung cancer

Collin is a medical oncologist specializing in the treatment of lung cancer. He received his Bachelor of Science degree in Molecular and Cellular Biology from the University of Washington and attended the Perelman School of Medicine at the University of Pennsylvania in the Medical Scientist Training Program. He completed his Internal Medicine residency at the Hospital of the University of Pennsylvania and trained as a clinical fellow in Medical Oncology at UCSF. His research focuses on understanding the cellular and molecular mechanisms underlying lung cancer resistance to EGFR-targeted therapies. His goal is to translate laboratory-based findings into new treatments for lung cancer patients.

Data provided by UCSF Profiles, powered by CTSI at UCSF
  • Damon Runyon Clinical Investigator Award, Damon Runyon Cancer Research Foundation, 2018-2021
  • V Scholar Award, V Foundation, 2018-2020
  • Clinical Scientist Award, Doris Duke Charitable Foundation, 2018-2012
  • AACR BioOncology Fellowship, AACR, 2014-2016
  • Legacy Award, Uniting Against Lung Cancer, 2014-2016
  • Research Grant, Bonnie J. Addario Lung Cancer Foundation, 2013

The primary focus of my research is to translate laboratory-based findings into novel investigator sponsored trials that aim to assess the safety and efficacy of rationally designed targeted therapies for lung cancer patients.

My goals are to: 1) define how TKI resistance pathways evolve at the tumor genome, transcriptome and molecular signaling levels within lung cancers and to translate these findings into novel prognostic and predictive biomarkers that may predict TKI resistance before it occurs; 2) develop investigator sponsored clinical trials to test rational companion therapies that can prevent, delay, or overcome TKI resistance, 3) develop investigator sponsored clinical trials to target recently identified oncogenic pathways, outside of EGFR and ALK, that drive NSCLC; and 4) establish a cohort of patient-derived xenograft (PDX) mice to foster research that aims to further understand the molecular mechanisms of response and resistance to TKI therapies in lung cancer

Data provided by UCSF Profiles, powered by CTSI
MOST RECENT PUBLICATIONS FROM A TOTAL OF 32
Data provided by UCSF Profiles, powered by CTSI
  1. Blakely CM, McCoach CE. Role of MPR as an Early Signal for Efficacy in Neoadjuvant Studies. Clin Cancer Res. 2020 Jul 15; 26(14):3499-3500. View in PubMed
  2. Gini B, Thomas N, Blakely CM. Impact of concurrent genomic alterations in epidermal growth factor receptor (EGFR)-mutated lung cancer. J Thorac Dis. 2020 May; 12(5):2883-2895. View in PubMed
  3. Doebele RC, Drilon A, Paz-Ares L, Siena S, Shaw AT, Farago AF, Blakely CM, Seto T, Cho BC, Tosi D, Besse B, Chawla SP, Bazhenova L, Krauss JC, Chae YK, Barve M, Garrido-Laguna I, Liu SV, Conkling P, John T, Fakih M, Sigal D, Loong HH, Buchschacher GL, Garrido P, Nieva J, Steuer C, Overbeck TR, Bowles DW, Fox E, Riehl T, Chow-Maneval E, Simmons B, Cui N, Johnson A, Eng S, Wilson TR, Demetri GD. Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials. Lancet Oncol. 2020 02; 21(2):271-282. View in PubMed
  4. Blakely CM, Riess JW. Interpretation of ceritinib clinical trial results and future combination therapy strategies for ALK-rearranged NSCLC. Expert Rev Anticancer Ther. 2019 12; 19(12):1061-1075. View in PubMed
  5. Blakely CM. A New Pathway Emerges to Interpret Lung Cancer Genomic Alterations. Clin Cancer Res. 2019 12 15; 25(24):7269-7271. View in PubMed
  6. View All Publications

 

Site Directory
    X